Boston Unions Fire Back at Wu's GLP-1 Coverage Ultimatum

In a heated standoff over escalating health insurance costs, the Public Employee Committee (PEC)—representing City of Boston unions—has pushed back against Mayor Michelle Wu's administration ultimatum to implement utilization management for GLP-1 drugs like Ozempic and Wegovy. The dispute centers on prior authorization requirements for these popular weight loss medications, which the city claims are driving budget strains. This clash highlights the growing tension between controlling public sector healthcare spending and employee access to transformative therapies.

The Administration's Push for Cost Controls

Boston's Chief Financial Officer Ashley Groffenberger outlined the urgency in a letter to the City Council, warning of a 22.6% premium increase for non-Medicare plans from FY26 to FY27—the highest in recent history. GLP-1 usage for weight loss accounts for 14.7% of this projected hike, despite only 7.7% of eligible employees using the drugs. Costs are estimated at $31.6 million for FY26, ballooning to $47.4 million in FY27 amid constrained revenue growth.

The Wu administration proposed utilization management (UM) starting July 1 for fiscal year 2027, requiring prior authorization for prescriptions. Groffenberger projected $8-9 million in annual savings. After PEC's March 9 rejection—driven by unions like the Boston Teachers Union and Boston Firefighters Local 718—the city urged a revote by Friday, calling the initial decision hasty due to short notice and absentee unions.

The consequences of this inaction, if allowed to stand, are massive and immediate.

Ashley Groffenberger, Boston CFO

Unions' Counter-Offer and Defiance

Elissa Cadillic, PEC co-chair and head of AFSCME Local 1526 (Boston Public Library Employees Union), described the city's stance as an "ultimatum" rather than a formal offer. In a letter to the administration, PEC proposed delaying UM to January 1—halfway through FY27—and extending union health benefits contracts by a year, set to expire June 30, 2027.

"The unions have gotten together and have made what we view is a good-faith response," Cadillic told the Herald. She disputed savings claims, noting no "definitive evidence" UM would reduce costs, and raised concerns about it expanding to other medications. PEC was also alarmed by threats to switch to the Commonwealth's Group Insurance Commission (GIC), which eliminated GLP-1 weight loss coverage for state employees, causing "immense" disruption with minimal city savings.

Cadillic emphasized, "It's not a rejection of an offer... We've put an offer out to extend, to say, 'Look, this is what we're willing to reconsider.'"

What Are GLP-1 Drugs and Why the Cost Surge?

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide mimic glucagon-like peptide-1 hormones, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Originally for type 2 diabetes, they're now widely prescribed for obesity, leading to 15-20% average weight loss in trials. This efficacy has fueled demand, but high list prices—around $1,000-$1,500 monthly—plus off-label use have skyrocketed insurer costs nationwide.

In public plans like Boston's, low utilization (7.7%) belies outsized impact due to expense. Utilization management, via prior authorization, ensures medical necessity (e.g., BMI ≥30 or ≥27 with comorbidities), curbing cosmetic misuse while preserving access for qualified patients.

Mechanisms Behind Popularity

• Appetite suppression: Activates brain receptors to signal fullness.
• Glucose control: Enhances insulin release, lowers blood sugar.
• Cardiovascular benefits: Reduced risks in diabetes patients, though weight loss focus here.

For Boston employees, these drugs offer metabolic health tools, but unchecked growth threatens premiums affecting all.

Internal Union Divisions Emerge

Not all unions align with PEC's stance. Boston Police Patrolmen's Association and SEIU Local 888 voted for UM. SEIU President Thomas McKeever criticized the "hard line," warning of layoffs for low-wage members without negotiations.

"If we don't have those discussions, then the majority of citywide unions will be facing layoffs," McKeever said. "They're taking a hard line against the mayor and refusing to open the contract." A source noted the rejection stemmed from "hostility immediately out of the gate."

Implications for Boston City Employees

City workers and retirees face premium hikes without resolution. Prior authorization typically requires documenting obesity-related conditions, BMI, and failed prior therapies—steps delaying access but promoting appropriate use. Employees should discuss with providers: Is GLP-1 right for diabetes/obesity management? Tools like Shotlee can help track symptoms, side effects (nausea, GI issues), and adherence during waits.

Safety profile: Common side effects include gastrointestinal upset (20-40% users), mitigated by dose titration. Rare risks like pancreatitis or thyroid tumors warrant monitoring. Compared to alternatives (phentermine, bariatric surgery), GLP-1s offer non-invasive, sustained results but at premium cost.

Patient Guidance

• Verify coverage status with HR/benefits team.
• Prepare BMI, weight history, and comorbidity docs for PA.
• Explore generics or compounded versions if allowed.
• Monitor budget updates via city announcements.

Broader Context: GLP-1 Coverage Nationwide

Boston mirrors trends: GIC's cut, employer pushback (e.g., UPS, Walmart caps). UM balances access/costs, with studies showing 30-50% PA denial reversal on appeal. For metabolic health, GLP-1s transform outcomes—15% weight loss cuts diabetes risk 50%—but fiscal reality demands stewardship.

Key Takeaways

• City projects $8-9M UM savings vs. $47.4M FY27 GLP-1 spend.
• PEC counters with Jan. 1 start, contract extension.
• Divided unions: Some favor cuts to avert layoffs.
• Employees: Prepare for PA; discuss necessity with MD.

Conclusion

This dispute underscores GLP-1s' double-edged sword: life-changing for metabolic health, burdensome for budgets. Watch for Wu administration response to PEC's offer. Boston employees, consult doctors on alternatives and track changes—proactive steps ensure informed access amid uncertainty.